{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:23:27Z","timestamp":1791069807769,"version":"4.1.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1038\/ncponc1000","type":"journal-article","created":{"date-parts":[[2007,11,23]],"date-time":"2007-11-23T14:37:20Z","timestamp":1195828640000},"page":"711-721","source":"Crossref","is-referenced-by-count":75,"title":["Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle"],"prefix":"10.1038","volume":"4","author":[{"given":"Francesco","family":"Bertoldo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Lo Cascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncponc1000_CR1","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1093\/annonc\/mdg401","volume":"14","author":"D Santini","year":"2003","unstructured":"Santini D et al. (2003) The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14: 1468\u20131476","journal-title":"Ann Oncol"},{"key":"BFncponc1000_CR2","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-05-0264","volume":"65","author":"P Clezardin","year":"2005","unstructured":"Clezardin P et al. (2005) Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 65: 4971\u20134974","journal-title":"Cancer Res"},{"key":"BFncponc1000_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/bmj.327.7413.469","volume":"327","author":"JR Ross","year":"2003","unstructured":"Ross JR et al. (2003) Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 327: 469\u2013472","journal-title":"BMJ"},{"key":"BFncponc1000_CR4","doi-asserted-by":"publisher","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","volume":"144","author":"SB Woo","year":"2006","unstructured":"Woo SB et al. (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144: 753\u2013761","journal-title":"Ann Intern Med"},{"key":"BFncponc1000_CR5","doi-asserted-by":"publisher","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A et al. (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23: 8580\u20138587","journal-title":"J Clin Oncol"},{"key":"BFncponc1000_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/cncr.21130","volume":"104","author":"CA Migliorati","year":"2005","unstructured":"Migliorati CA et al. (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104: 83\u201393","journal-title":"Cancer"},{"key":"BFncponc1000_CR7","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","volume":"24","author":"A Badros","year":"2006","unstructured":"Badros A et al. (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24: 945\u2013952","journal-title":"J Clin Oncol"},{"key":"BFncponc1000_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","volume":"65","author":"T Mavrokokki","year":"2007","unstructured":"Mavrokokki T et al. (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65: 415\u2013423","journal-title":"J Oral Maxillofac Surg"},{"key":"BFncponc1000_CR9","unstructured":"Hoff A et al. (2006) Osteonecrosis of the jaw in patients receiving intravenous bisphosphonates therapy [abstract #8528]. J Clin Oncol (Suppl 24): S475"},{"key":"BFncponc1000_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1034\/j.1600-0722.2003.00067.x","volume":"111","author":"L Bonafe-Oliveira","year":"2003","unstructured":"Bonafe-Oliveira L et al. (2003) Ultrastructural and histochemical examination of alveolar bone at the pressure areas of rat molars submitted to continuous orthodontic force. Eur J Oral Sci 111: 410\u2013416","journal-title":"Eur J Oral Sci"},{"key":"BFncponc1000_CR11","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1067\/mod.2001.118623","volume":"120","author":"WJ Rody Jr","year":"2001","unstructured":"Rody WJ Jr et al. (2001) Osteoclast recruitment to sites of compression in orthodontic tooth movement. Am J Orthod Dentofascial Orthop 120: 477\u2013489","journal-title":"Am J Orthod Dentofascial Orthop"},{"key":"BFncponc1000_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/oxfordjournals.jmicro.a023623","volume":"47","author":"M Shimizu","year":"1998","unstructured":"Shimizu M et al. (1998) Bone wound healing after maxillary molar extraction in ovariectomized aged rats. J Electron Microsc (Tokyo) 47: 517\u2013526","journal-title":"J Electron Microsc (Tokyo)"},{"key":"BFncponc1000_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1600-0765.1994.tb01095.x","volume":"29","author":"S Pitaru","year":"1994","unstructured":"Pitaru S et al. (1994) Cellular origins and differentiation control mechanisms during periodontal development and wound healing. J Periodontal Res 29: 81\u201394","journal-title":"J Periodontal Res"},{"key":"BFncponc1000_CR14","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1359\/jbmr.2000.15.10.1924","volume":"15","author":"Y Kobayashi","year":"2000","unstructured":"Kobayashi Y et al. (2000) Forced-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor \u03b2 and osteoprotegerin expression. J Bone Min Res 15: 1924\u20131934","journal-title":"J Bone Min Res"},{"key":"BFncponc1000_CR15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1359\/jbmr.1999.14.6.839","volume":"14","author":"K Terai","year":"1999","unstructured":"Terai K et al. (1999) Role of osteopontin in bone remodeling caused by mechanical stress. J Bone Miner Res 14: 839\u2013849","journal-title":"J Bone Miner Res"},{"key":"BFncponc1000_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1359\/jbmr.2002.17.2.210","volume":"17","author":"H Kanzaki","year":"2002","unstructured":"Kanzaki H et al. (2002) Periodontal ligament cells under mechanical stress induce osteoclastogenesis by receptor activator of nuclear factor \u03baB ligand up-regulation via prostaglandin E2 synthesis. J Bone Miner Res 17: 210\u2013220","journal-title":"J Bone Miner Res"},{"key":"BFncponc1000_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/154405910508400407","volume":"84","author":"H Fukushima","year":"2005","unstructured":"Fukushima H et al. (2005) Parathyroid-hormone-related protein induces expression of receptor activator of NF-\u03baB ligand in human periodontal ligament cells via a cAMP\/protein kinase A-independent pathway. J Dent Res 84: 329\u2013334","journal-title":"J Dent Res"},{"key":"BFncponc1000_CR18","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1902\/jop.2005.76.7.1123","volume":"76","author":"M Tezal","year":"2005","unstructured":"Tezal M et al. (2005) Periodontal disease and the incidence of tooth loss in postmenopausal women. J Periodontol 76: 1123\u20131128","journal-title":"J Periodontol"},{"key":"BFncponc1000_CR19","unstructured":"[No authors listed] (1996) Position paper: Epidemiology of periodontal diseases. American Academy of Periodontology. J Periodontol 67: 935\u2013945"},{"key":"BFncponc1000_CR20","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1034\/j.1600-0765.2003.00615.x","volume":"38","author":"T Crotti","year":"2003","unstructured":"Crotti T et al. (2003) Receptor activator NF kappa B ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 38: 380\u2013387","journal-title":"J Periodontal Res"},{"key":"BFncponc1000_CR21","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1902\/jop.2004.75.12.1586","volume":"75","author":"R Vernal","year":"2004","unstructured":"Vernal R et al. (2004) Levels of cytokine receptor activator of nuclear factor kB ligand in gingival crevicular fluid in untreated chronic periodontitis patients. J Periodontol 75: 1586\u20131591","journal-title":"J Periodontol"},{"key":"BFncponc1000_CR22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00784-005-0303-x","volume":"9","author":"HP M\u00fcller","year":"2005","unstructured":"M\u00fcller HP and Ulbrich M (2005) Alveolar bone levels in adults as assessed on panoramic radiographs. (I) Prevalence, extent, and severity of even and angular bone loss. Clin Oral Investig 9: 98\u2013104","journal-title":"Clin Oral Investig"},{"key":"BFncponc1000_CR23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0022-3913(98)70116-7","volume":"80","author":"L Jahangari","year":"1998","unstructured":"Jahangari L et al. (1998) Current perspectives in residual ridge remodeling and its clinical implication: a review. J Prosthet Dent 80: 224\u2013237","journal-title":"J Prosthet Dent"},{"key":"BFncponc1000_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.coph.2006.03.005","volume":"6","author":"FP Coxon","year":"2006","unstructured":"Coxon FP et al. (2006) Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 6: 307\u2013312","journal-title":"Curr Opin Pharmacol"},{"key":"BFncponc1000_CR25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.bone.2006.01.141","volume":"38","author":"SE Papapoulos","year":"2006","unstructured":"Papapoulos SE (2006) Bisphosphonate actions: physical chemistry revisited. Bone 38: 613\u2013616","journal-title":"Bone"},{"key":"BFncponc1000_CR26","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.2174\/1381612033453640","volume":"9","author":"MJ Rogers","year":"2003","unstructured":"Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9: 2643\u20132658","journal-title":"Curr Pharm Des"},{"key":"BFncponc1000_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","volume":"19","author":"H Fleisch","year":"1998","unstructured":"Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19: 80\u2013100","journal-title":"Endocr Rev"},{"issue":"Suppl 20","key":"BFncponc1000_CR28","doi-asserted-by":"publisher","first-page":"S6222","DOI":"10.1158\/1078-0432.CCR-06-0843","volume":"12","author":"AJ Roelofs","year":"2006","unstructured":"Roelofs AJ et al. (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12 (Suppl 20): S6222\u2013S6230","journal-title":"Clin Cancer Res"},{"key":"BFncponc1000_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.bone.2005.04.021","volume":"37","author":"FP Coxon","year":"2005","unstructured":"Coxon FP et al. (2005) Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone 37: 349\u2013358","journal-title":"Bone"},{"key":"BFncponc1000_CR30","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR et al. (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346: 653\u2013661","journal-title":"N Engl J Med"},{"key":"BFncponc1000_CR31","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJMoa044241","volume":"353","author":"IR Reid","year":"2005","unstructured":"Reid IR et al. (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 353: 898\u2013908","journal-title":"N Engl J Med"},{"key":"BFncponc1000_CR32","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"D Black","year":"2006","unstructured":"Black D et al. (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term EXtension (FLEX): a randomized trial. J Am Med Ass 296: 2927\u20132938","journal-title":"J Am Med Ass"},{"issue":"3","key":"BFncponc1000_CR33","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","volume":"19","author":"N. B. Watts","year":"2007","unstructured":"Watts NB et al. (2007) Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int [doi:10.1007\/s00198-007-0460-7]","journal-title":"Osteoporosis International"},{"key":"BFncponc1000_CR34","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1210\/jcem.80.12.8530584","volume":"80","author":"JO Landman","year":"1995","unstructured":"Landman JO et al. (1995) Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab 80: 3465\u20133468","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncponc1000_CR35","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/8756-3282(96)00182-2","volume":"19","author":"P Masarachia","year":"1996","unstructured":"Masarachia P et al. (1996) Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19: 281\u2013290","journal-title":"Bone"},{"key":"BFncponc1000_CR36","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2165\/00003088-200544060-00001","volume":"44","author":"S Cremers","year":"2005","unstructured":"Cremers S et al. (2005) Pharmacokinetics\/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44: 551\u2013570","journal-title":"Clin Pharmacokinet"},{"key":"BFncponc1000_CR37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/j.1552-4604.1997.tb04304.x","volume":"37","author":"JR Berenson","year":"1997","unstructured":"Berenson JR et al. (1997) Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 37: 285\u2013290","journal-title":"J Clin Pharmacol"},{"key":"BFncponc1000_CR38","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1359\/jbmr.2003.18.5.868","volume":"18","author":"SC Cremers","year":"2003","unstructured":"Cremers SC et al. (2003) Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone. J Bone Miner Res 18: 868\u2013875","journal-title":"J Bone Miner Res"},{"key":"BFncponc1000_CR39","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1359\/JBMR.050522","volume":"20","author":"SC Cremers","year":"2005","unstructured":"Cremers SC et al. (2005) Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. J Bone Miner Res 20: 1543\u20131547","journal-title":"J Bone Miner Res"},{"key":"BFncponc1000_CR40","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1006\/ijom.2002.0472","volume":"33","author":"H Altundal","year":"2004","unstructured":"Altundal H and Guvener O (2004) The effect of alendronate on resorption of the alveolar bone following tooth extraction. Int J Oral Maxillofac Surg 33: 286\u2013293","journal-title":"Int J Oral Maxillofac Surg"},{"key":"BFncponc1000_CR41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1600-0765.1994.tb01088.x","volume":"29","author":"M Weireb","year":"1994","unstructured":"Weireb M et al. (1994) Istomorphometrical analysis of the effects of the bisphosphonates alendronate on bone loss caused by experimental periodontitis in monkeys. J Periodontal Res 29: 35\u201340","journal-title":"J Periodontal Res"},{"key":"BFncponc1000_CR42","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1067\/mod.2001.118623","volume":"120","author":"WJ Rody","year":"2001","unstructured":"Rody WJ et al. (2001) Osteoclast recruitment to sites of compression in orthodontic tooth movement. Am J Orthod Denofacial Orthop 120: 477\u2013489","journal-title":"Am J Orthod Denofacial Orthop"},{"key":"BFncponc1000_CR43","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.bone.2005.09.018","volume":"38","author":"H Shell","year":"2006","unstructured":"Shell H et al. (2006) Osteoclast activity begins early and increase over the course of bone healing. Bone 38: 547\u2013554","journal-title":"Bone"},{"issue":"Suppl 1","key":"BFncponc1000_CR44","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S8756-3282(96)00138-X","volume":"19","author":"TA Linkhart","year":"1996","unstructured":"Linkhart TA et al. (1996) Growth factors for bone growth and repair: IGF, TGF-beta, and BMP. Bone 19 (Suppl 1): S1\u2013S12","journal-title":"Bone"},{"key":"BFncponc1000_CR45","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1359\/jbmr.2002.17.3.513","volume":"17","author":"TJ Cho","year":"2002","unstructured":"Cho TJ et al. (2002) Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res 17: 513\u2013520","journal-title":"J Bone Miner Res"},{"key":"BFncponc1000_CR46","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S0278-2391(03)00319-7","volume":"61","author":"Z Lalani","year":"2003","unstructured":"Lalani Z et al. (2003) Spatial and temporal localization of transforming growth factor-beta1, bone morphogenetic protein\u20132, and platelet-derived growth factor-A in healing tooth extraction sockets in a rabbit model. J Oral Maxillofac Surg 61: 1061\u20131072","journal-title":"J Oral Maxillofac Surg"},{"key":"BFncponc1000_CR47","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0003-9969(96)00063-5","volume":"41","author":"S Uematsu","year":"1997","unstructured":"Uematsu S et al. (1997) Increase of transforming growth factor-beta 1 in gingival crevicular fluid during human orthodontic tooth movement. Arch Oral Biol 41: 1091\u20131095","journal-title":"Arch Oral Biol"},{"key":"BFncponc1000_CR48","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1600-0722.2006.00381.x","volume":"114","author":"W G\u00f6tz","year":"2006","unstructured":"G\u00f6tz W et al. (2006) Insulin-like growth factor system components in the periodontium during tooth root resorption and early repair process in the rat. Eur J Oral Sci 114: 318\u2013327","journal-title":"Eur J Oral Sci"},{"key":"BFncponc1000_CR49","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/annonc\/mdl294","volume":"17","author":"T Van den Wyngaert","year":"2006","unstructured":"Van den Wyngaert T et al. (2006) Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann Oncol 17: 1197\u20131204","journal-title":"Ann Oncol"},{"key":"BFncponc1000_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/jop.2006.2.1.7","volume":"2","author":"S Ruggiero","year":"2006","unstructured":"Ruggiero S et al. (2006) Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2: 7\u201314","journal-title":"J Oncol Pract"},{"key":"BFncponc1000_CR51","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S0268-0033(02)00108-0","volume":"17","author":"LE Bilston","year":"2002","unstructured":"Bilston LE et al. (2002) Zoledronic acid improves the mechanical properties of normal and healing bone. Clin Biomech (Bristol, Avon) 17: 716\u2013718","journal-title":"Clin Biomech (Bristol, Avon)"},{"key":"BFncponc1000_CR52","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S8756-3282(01)00414-8","volume":"28","author":"T Mashiba","year":"2001","unstructured":"Mashiba T et al. (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28: 524\u2013531","journal-title":"Bone"},{"key":"BFncponc1000_CR53","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1359\/jbmr.2002.17.12.2237","volume":"17","author":"Y Cao","year":"2002","unstructured":"Cao Y et al. (2002) Raloxifene, estrogen and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 17: 2237\u20132246","journal-title":"J Bone Miner Res"},{"issue":"Suppl 7","key":"BFncponc1000_CR54","first-page":"S53","volume":"5","author":"AE Goodship","year":"1994","unstructured":"Goodship AE et al. (1994) Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. Ann Oncol 5 (Suppl 7): S53\u2013S55","journal-title":"Ann Oncol"},{"key":"BFncponc1000_CR55","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1600-0714.2006.00391.x","volume":"35","author":"T Hansen","year":"2006","unstructured":"Hansen T et al. (2006) Osteonecrosis of the jaws in patients treated with bisphosphonates\u2014histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35: 155\u2013160","journal-title":"J Oral Pathol Med"},{"key":"BFncponc1000_CR56","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1754-4505.2002.tb01178.x","volume":"22","author":"EC Sung","year":"2002","unstructured":"Sung EC et al. (2002) Osteonecrosis of the maxilla as a complication to chemotherapy: a case report. Spec Care Dentist 22: 142\u2013146","journal-title":"Spec Care Dentist"},{"key":"BFncponc1000_CR57","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ijom.2005.01.003","volume":"34","author":"S Hino","year":"2005","unstructured":"Hino S et al. (2005) Response of diffuse sclerosing osteomyelitis of the mandible to alendronate: follow-up study by 99mTc scintigraphy. Int J Oral Maxillofac Surg 34: 576\u2013578","journal-title":"Int J Oral Maxillofac Surg"},{"key":"BFncponc1000_CR58","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","volume":"62","author":"SL Ruggiero","year":"2004","unstructured":"Ruggiero SL et al. (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62: 527\u2013534","journal-title":"J Oral Maxillofac Surg"},{"key":"BFncponc1000_CR59","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.joms.2005.01.010","volume":"63","author":"JW Hellstein","year":"2005","unstructured":"Hellstein JW and Marek CL (2005) Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 63: 682\u2013689","journal-title":"J Oral Maxillofac Surg"},{"key":"BFncponc1000_CR60","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.joms.2003.11.009","volume":"62","author":"LA Assael","year":"2004","unstructured":"Assael LA (2004) New foundations in understanding osteonecrosis of the jaws. J Oral Maxillofac Surg 62: 125\u2013126","journal-title":"J Oral Maxillofac Surg"},{"key":"BFncponc1000_CR61","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/j.1526-4637.2004.04038.x","volume":"5","author":"JN Robinson","year":"2004","unstructured":"Robinson JN et al. (2004) Efficacy of pamidronate in complex regional pain syndrome type I. Pain Med 5: 276\u2013280","journal-title":"Pain Med"},{"key":"BFncponc1000_CR62","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1124\/jpet.102.035295","volume":"302","author":"J Wood","year":"2002","unstructured":"Wood J et al. (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302: 1055\u20131061","journal-title":"J Pharmacol Exp Ther"},{"key":"BFncponc1000_CR63","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1089\/jir.2005.25.144","volume":"25","author":"B Vincenzi","year":"2005","unstructured":"Vincenzi B et al. (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25: 144\u2013151","journal-title":"J Interferon Cytokine Res"},{"key":"BFncponc1000_CR64","first-page":"6538","volume":"62","author":"P Fournier","year":"2002","unstructured":"Fournier P et al. (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62: 6538\u20136544","journal-title":"Cancer Res"},{"key":"BFncponc1000_CR65","first-page":"1080","volume":"8","author":"D Santini","year":"2002","unstructured":"Santini D et al. (2002) Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8: 1080\u20131084","journal-title":"Clin Cancer Res"},{"key":"BFncponc1000_CR66","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1359\/jbmr.2002.17.6.998","volume":"17","author":"MM Deckers","year":"2002","unstructured":"Deckers MM et al. (2002) Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. J Bone Miner Res 17: 998\u20131007","journal-title":"J Bone Miner Res"},{"key":"BFncponc1000_CR67","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s005200050253","volume":"7","author":"A Heimdahl","year":"1999","unstructured":"Heimdahl A (1999) Prevention and management of oral infections in cancer patient. Support Care Cancer 7: 224\u2013228","journal-title":"Support Care Cancer"},{"key":"BFncponc1000_CR68","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1368-8375(97)00053-5","volume":"34","author":"ST Sonis","year":"1998","unstructured":"Sonis ST (1998) Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34: 39\u201343","journal-title":"Oral Oncol"},{"key":"BFncponc1000_CR69","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s00520-002-0346-3","volume":"10","author":"JE Raber-Durlacher","year":"2002","unstructured":"Raber-Durlacher JE et al. (2002) Periodontal infection in cancer patients treated with high-dose chemotherapy. Support Care Cancer 10: 466\u2013473","journal-title":"Support Care Cancer"},{"key":"BFncponc1000_CR70","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1902\/jop.2004.75.12.1647","volume":"75","author":"S Tiranathanagul","year":"2004","unstructured":"Tiranathanagul S et al. (2004) Actinobacillus actinomycetemcomitans lipopolysaccharide activates matrix metalloproteinase-2 and increases receptor activator of nuclear factor-\u03baB ligand expression in human periodontal ligament cells. J Periodontol 75: 1647\u20131654","journal-title":"J Periodontol"},{"key":"BFncponc1000_CR71","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1034\/j.1600-051x.2001.028002137.x","volume":"28","author":"N Narani","year":"2001","unstructured":"Narani N and Epstein JB (2001) Classifications of oral lesions in HIV infection. J Clin Periodontol 28: 137\u2013145","journal-title":"J Clin Periodontol"},{"key":"BFncponc1000_CR72","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","volume":"296","author":"JE Dunford","year":"2001","unstructured":"Dunford JE et al. (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296: 235\u2013242","journal-title":"J Pharmacol Exp Ther"},{"key":"BFncponc1000_CR73","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/jbmr.5650090521","volume":"9","author":"JR Green","year":"1994","unstructured":"Green JR et al. (1994) Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9: 745\u2013751","journal-title":"J Bone Miner Res"},{"key":"BFncponc1000_CR74","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1359\/JBMR.040920","volume":"20","author":"CJ Rosen","year":"2005","unstructured":"Rosen CJ et al. (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double blind study. J Bone Miner Res 20: 141\u2013151","journal-title":"J Bone Miner Res"},{"key":"BFncponc1000_CR75","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1177\/0091270004267594","volume":"44","author":"J Barret","year":"2004","unstructured":"Barret J et al. (2004) Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 44: 951\u2013965","journal-title":"J Clin Pharmacol"},{"key":"BFncponc1000_CR76","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/0009-9236(95)90245-7","volume":"58","author":"BJ Gertz","year":"1995","unstructured":"Gertz BJ et al. (1995) Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58: 288\u2013298","journal-title":"Clin Pharmacol Ther"},{"key":"BFncponc1000_CR77","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/annonc\/mdi162","volume":"16","author":"RE Coleman","year":"2005","unstructured":"Coleman RE (2005) Bisphosphonates in breast cancer. Ann Oncol 16: 687\u2013695","journal-title":"Ann Oncol"},{"key":"BFncponc1000_CR78","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1097\/00000421-200212001-00003","volume":"25","author":"Pierre P. Major","year":"2002","unstructured":"Major PP and Cook R (2002) Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol (Suppl 1): S10\u2013S18","journal-title":"American Journal of Clinical Oncology"},{"key":"BFncponc1000_CR79","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","volume":"90","author":"JJ Body","year":"2004","unstructured":"Body JJ et al. (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: result from two randomised, placebo-controlled phase III studies. Br J Cancer 90: 1133\u20131137","journal-title":"Br J Cancer"},{"key":"BFncponc1000_CR80","first-page":"968","volume":"9","author":"MA Dimopoulos","year":"2006","unstructured":"Dimopoulos MA et al. (2006) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 9: 968\u2013971","journal-title":"Haematologica"},{"key":"BFncponc1000_CR81","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/annonc\/mdl294","volume":"17","author":"T Van den Wyngaer","year":"2006","unstructured":"Van den Wyngaer T et al. (2006) Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann Oncol 17: 1197\u20131204","journal-title":"Ann Oncol"},{"key":"BFncponc1000_CR82","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1056\/NEJMp068157","volume":"355","author":"JP Bilezikian","year":"2006","unstructured":"Bilezikian JP (2006) Osteonecrosis of the jaw: do bisphosphonates pose a risk? N Engl J Med 355: 2278\u20132281","journal-title":"N Engl J Med"},{"issue":"Suppl 7","key":"BFncponc1000_CR83","first-page":"S38","volume":"14","author":"C Christiansen","year":"2003","unstructured":"Christiansen C et al. (2003) Comparison of risedronate and alendronate pharmacokinetics at clinical doses [abstract #P163]. Osteoporosis Int 14 (Suppl 7): S38","journal-title":"Osteoporosis Int"},{"key":"BFncponc1000_CR84","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Eng J Med 356: 1809\u20131822","journal-title":"N Eng J Med"},{"key":"BFncponc1000_CR85","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1038\/sj.bjc.6601437","volume":"89","author":"JE Brown","year":"2003","unstructured":"Brown JE et al. (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89: 2031\u20132037","journal-title":"Br J Cancer"},{"key":"BFncponc1000_CR86","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","volume":"23","author":"RE Coleman","year":"2005","unstructured":"Coleman RE et al. (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23: 4925\u20134935","journal-title":"J Clin Oncol"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncponc1000.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc1000","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc1000.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T20:55:54Z","timestamp":1737579354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc1000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":86,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["BFncponc1000"],"URL":"https:\/\/doi.org\/10.1038\/ncponc1000","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}